ScreenerHero

ALXO ALX Oncology Holdings Inc.

NAS · US · Healthcare · Biotechnology · alxoncology.com
1.130USD+1.80%Mkt Cap: 156.25M $P/E: —

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap156.25M USD
Enterprise Value26.30M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-101.69M USD
Revenue/Share—
Last Price1.130 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees48
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.06
PEG—
EV/EBITDA-0.32
EV/Revenue—
P/S—
P/B1.13
EPS (TTM)-1.04
EPS (Forward)-0.54
52W Range
1.0505% of range2.660
52W High2.660 USD
52W Low1.050 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-391.42%
ROA-172.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-84.14M USD
CapEx (TTM)212.00K USD
FCF Margin—
FCF Yield-26.34%
Net Debt-127.19M USD
Net Debt/EBITDA1.55
Balance Sheet
Debt/Equity0.38
Current Ratio9.71
Quick Ratio9.43
Book Value/Sh0.98 USD
Cash/Share1.00 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.600 USD
Upside (mean)+307.1%
Target Range4.000 USD – 6.000 USD
4.000+307.1% to mean6.000
# Analysts5
Ownership
Shares Out.138.28M
Float94.71M
Insiders0.89%
Institutions84.70%
Short Interest
Short Ratio9.0d
Short % Float5.03%
Short % Out.4.54%
Shares Short6.27M
Short (prev mo.)7.61M
Technical
SMA 501.838 (-38.5%)
SMA 2001.840 (-38.6%)
Beta0.48
S&P 52W Chg16.45%
Avg Vol (30d)1.15M
Avg Vol (10d)1.49M
Technical Indicators
RSI (14)23.8
MACD-0.2050
MACD Signal-0.1691
MACD Hist.-0.0359
BB Upper2.133 USD
BB Middle1.534 USD
BB Lower0.9363 USD
BB Width77.97%
ATR (14)0.1224 USD
Vol Ratio (20d)0.56x